IL124811A0 - Beta-adrenergic agonists to reduce a wasting condition - Google Patents
Beta-adrenergic agonists to reduce a wasting conditionInfo
- Publication number
- IL124811A0 IL124811A0 IL12481198A IL12481198A IL124811A0 IL 124811 A0 IL124811 A0 IL 124811A0 IL 12481198 A IL12481198 A IL 12481198A IL 12481198 A IL12481198 A IL 12481198A IL 124811 A0 IL124811 A0 IL 124811A0
- Authority
- IL
- Israel
- Prior art keywords
- beta
- reduce
- adrenergic agonists
- wasting condition
- wasting
- Prior art date
Links
- 239000000808 adrenergic beta-agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4958497P | 1997-06-13 | 1997-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL124811A0 true IL124811A0 (en) | 1999-01-26 |
Family
ID=21960612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12481198A IL124811A0 (en) | 1997-06-13 | 1998-06-08 | Beta-adrenergic agonists to reduce a wasting condition |
Country Status (9)
Country | Link |
---|---|
US (1) | US6001856A (xx) |
EP (1) | EP0887079A1 (xx) |
JP (1) | JPH1192372A (xx) |
KR (1) | KR19990006931A (xx) |
AU (1) | AU7006398A (xx) |
CA (1) | CA2240312A1 (xx) |
HU (1) | HUP9801339A1 (xx) |
IL (1) | IL124811A0 (xx) |
ZA (1) | ZA985130B (xx) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
CA2362070A1 (en) * | 1999-02-16 | 2000-08-24 | Masaru Mitsuda | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active .beta.3 agonist by the use of the same |
US6531603B1 (en) | 2001-06-29 | 2003-03-11 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
US6657061B2 (en) | 2001-06-29 | 2003-12-02 | Grayson Walker Stowell | Polymorphic forms of 6-[4-1(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
US6660864B2 (en) | 2001-06-29 | 2003-12-09 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
US6573382B2 (en) | 2001-06-29 | 2003-06-03 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
US6388080B1 (en) | 2001-06-29 | 2002-05-14 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
US6596871B2 (en) | 2001-06-29 | 2003-07-22 | Grayson Walker Stowell | Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone |
WO2003072573A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
AU2003248352A1 (en) * | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS |
US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
WO2021217041A1 (en) * | 2020-04-24 | 2021-10-28 | Immvention Therapeutix | N-substituted alpha-amino and alpha-hydroxy carboxamide derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
US5561142A (en) * | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
MX9708621A (es) * | 1995-05-10 | 1998-02-28 | Pfizer | AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS. |
EP0828712A1 (en) * | 1995-05-10 | 1998-03-18 | Pfizer Inc. | Beta-adrenergic agonists |
US5597843A (en) * | 1995-06-07 | 1997-01-28 | Houghten Pharmaceuticals | Use of a substituted 1,3-benzodioxole to reduce a wasting condition |
GB2305665A (en) * | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
-
1998
- 1998-03-02 US US09/033,263 patent/US6001856A/en not_active Expired - Fee Related
- 1998-06-01 EP EP98304300A patent/EP0887079A1/en not_active Withdrawn
- 1998-06-08 IL IL12481198A patent/IL124811A0/xx unknown
- 1998-06-10 AU AU70063/98A patent/AU7006398A/en not_active Abandoned
- 1998-06-11 CA CA002240312A patent/CA2240312A1/en not_active Abandoned
- 1998-06-12 ZA ZA9805130A patent/ZA985130B/xx unknown
- 1998-06-12 KR KR1019980021896A patent/KR19990006931A/ko not_active Application Discontinuation
- 1998-06-12 JP JP10165561A patent/JPH1192372A/ja active Pending
- 1998-06-12 HU HU9801339A patent/HUP9801339A1/hu unknown
Also Published As
Publication number | Publication date |
---|---|
HUP9801339A1 (hu) | 2000-11-28 |
CA2240312A1 (en) | 1998-12-13 |
JPH1192372A (ja) | 1999-04-06 |
EP0887079A1 (en) | 1998-12-30 |
HU9801339D0 (en) | 1998-08-28 |
ZA985130B (en) | 1999-12-13 |
KR19990006931A (ko) | 1999-01-25 |
US6001856A (en) | 1999-12-14 |
AU7006398A (en) | 1998-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP9801356A0 (en) | Prostaglandin agonists | |
HU9603171D0 (en) | New agonist compounds | |
DE69803272D1 (en) | Hemmstoffe der stickstoffmonoxid-synthase | |
IL118115A0 (en) | Beta-adrenergic agonists | |
GB9701960D0 (en) | A cache system | |
ZA9510592B (en) | Estrogen agonists | |
IL124811A0 (en) | Beta-adrenergic agonists to reduce a wasting condition | |
PL336068A1 (en) | Pharmacological agents | |
EP0996458A4 (en) | SANDRAMYCIN ANALOG | |
GB9826359D0 (en) | Novel receptors | |
PL338428A1 (en) | Soap wrapping | |
TW497678U (en) | Grooved cylinder | |
AU137880S (en) | A wipe | |
ZA9810184B (en) | New phenyl-alkyl-imidazoles | |
HUP0004317A3 (en) | 5-ht1f agonists | |
ZA988950B (en) | Can end | |
EP0983296A4 (en) | RECEPTORS FOR TGF BETA RELATED NEUROTROPHIC FACTORS | |
GB9719470D0 (en) | Nocotinic receptors | |
LT97124A (en) | A piston | |
TW337359U (en) | A stow cylinder | |
ZA983615B (en) | Kappa opioid agonists | |
TW347655U (en) | Positioned structure for umbrella-drops | |
GB9706875D0 (en) | Solder dispenser | |
GB9711421D0 (en) | Metersaver cylinder | |
GB9715730D0 (en) | Free piston emgine |